

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma ID1441

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Immunocore (Tebentafusp) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Cancer 52 • Cancer Black Care • Cancer Equality • Eyecare Trust • Fight for Sight • Helen Rollason Cancer Charity • Independent Cancer Patients' Voice • Macmillan Cancer Support • Macular Society • Maggie's Centres • Marie Curie • Melanoma Fund • Melanoma UK • OcuMel UK • OBAC • The Royal National Institute of Blind People • SeeAbility • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Thomas Pocklington Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Optometrists • British Association of Surgical Oncology 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Council for the Blind • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb Pharmaceuticals (ipilimumab, nivolumab) • Medac GmbH (dacarbazine) • Merck Sharp & Dohme (pembrolizumab)

Final stakeholder list for the technology appraisal of tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma ID1441
Issue date: August 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • Cancer Research UK • College of Optometrists • Melanoma Focus • Optical Confederation • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS East Staffordshire CCG • NHS Greenwich CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Eyes and Vision Group • Cochrane Skin Group • Eyehope • Genomics England • Institute of Cancer Research • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Eye Research Centre • National Institute for Health Research • Pro Cancer Research Fund • Skin Cancer Research Fund <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient

Final stakeholder list for the technology appraisal of tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma ID1441
Issue date: August 2021

organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.